Research Reference
Tirzepatide
Dual GLP-1/GIP agonist — proven fat loss and glycemic control
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Tirzepatide is a dual GLP-1/GIP receptor agonist. Phase 3 trials documented superior weight loss and glycemic control compared to single-target GLP-1 agonists, with up to 22.5% body weight reduction at 72 weeks in the SURMOUNT-1 trial (Frias et al., 2021; Jastreboff et al., 2022).
Tirzepatide is FDA-approved (as a pharmaceutical product) for type 2 diabetes and chronic weight management. Research-peptide and compounded forms are not FDA-approved and are sold for research purposes only.
Community research-peptide protocols use lower doses than pharmaceutical formulations — commonly 0.25–0.5 mg 3x/week rather than the weekly titration to 15 mg used in the FDA-approved protocol.
Side Effects & Safety
- GI effects (most common): Nausea, diarrhea, constipation, reduced appetite — dose-dependent and most pronounced during titration
- Injection site reactions — redness or mild pain
- Fatigue or malaise — occasionally during dose escalation
- Hypoglycemia risk — low when used alone, higher with insulin or sulfonylureas
- Dehydration risk — GI fluid loss; maintain hydration
Research-peptide and compounded forms are not FDA-approved.
Research Basis
Tirzepatide is a dual GLP-1/GIP receptor agonist.
SURMOUNT-1 trial (Jastreboff et al., 2022): Up to 22.5% body weight reduction at 72 weeks — superior to single-target GLP-1 agonists.
Frias et al., 2021: Documented superior glycemic control and weight loss compared to single-target GLP-1 agonists in Phase 3 trials.
The dual mechanism (GLP-1 + GIP) produces greater weight loss than GLP-1 alone at comparable doses. Community research-peptide protocols use substantially lower doses than the FDA-approved pharmaceutical titration.